OTC monograph drug program user fees the US Food and Drug Administration requested for fiscal year 2022 are up slightly from the agency’s current budget, but the total amount it collects in the 12 months starting October could be much larger.
That’s because the payments the FDA receives under the program could expand from the facility fees from around 1,700 firms it received for the current fiscal year to include payments...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?